|
Sign In to gain access to subscriptions and/or personal tools.
|
Metabolic Syndrome and Cardiovascular Disease
Leslie Citrome
New York University School of Medicine, Department of Psychiatry, and the Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, citrome{at}nki.rfmh.org
Metabolic syndrome is a constellation of clinical findings that identify individuals at higher than normal risk of developing diabetes mellitus or cardiovascular disease. There are two principal definitions, one emerging from the American National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, and the other from the World Health Organization. Both definitions share the common elements of abdominal obesity, hypertriglyceridaemia, low HDL-cholesterol, hypertension and abnormal glucose regulation. The syndrome is relatively common across continents, and also among those without marked obesity. It is even more common among patients with major mental health disorders such as schizophrenia. Metabolic syndrome can be used to assess risk for cardiovascular disorder and death, and is an alternative to Framingham Risk Calculations. C-reactive protein may play an additional role in risk prediction. Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate.
Key Words: metabolic syndrome cardiovascular disease schizophrenia antipsychotics
Journal of Psychopharmacology, Vol. 19, No. 6 suppl,
84-93 (2005)
DOI: 10.1177/0269881105058375

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Bedi, N. Van Dam, and J. Redman
Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use
J Psychopharmacol,
February 1, 2010;
24(2):
233 - 240.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pirona and M. Morgan
An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users
J Psychopharmacol,
February 1, 2010;
24(2):
175 - 185.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Falck, Jichuan Wang, and R. G. Carlson
Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis
J Psychopharmacol,
January 1, 2008;
22(1):
47 - 54.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. I. Holt
Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome
The British Journal of Diabetes & Vascular Disease,
September 1, 2006;
6(5):
199 - 204.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Guillot and D. Greenway
Recreational ecstasy use and depression
J Psychopharmacol,
May 1, 2006;
20(3):
411 - 416.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Parrott
MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress
J Psychopharmacol,
March 1, 2006;
20(2):
147 - 163.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. L. de Win, T. Schilt, L. Reneman, H. Vervaeke, G. Jager, S. Dijkink, J. Booij, and W. van den Brink
Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study
J Psychopharmacol,
March 1, 2006;
20(2):
226 - 235.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Bushe, P. Haddad, R. Peveler, and J. Pendlebury
The role of lifestyle interventions and weight management in schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
28 - 35.
[Abstract]
[PDF]
|
 |
|
|
|